Hyperbaric Chamber Improved Cognitive Function Circulation Circular Arc Hyperbaric Chamber Sitting Single Room WEIZI
Overview
What is Micro Hyperbaric Oxygen Therapy?
Micro Hyperbaric Oxygen Therapy (MHBOT) represents a cutting-edge medical procedure that utilizes a pressurized chamber filled with highly concentrated oxygen, typically achieving a purity of 96%, to enhance the delivery of oxygen to the body's tissues. This innovative approach exploits the principle that increased pressure facilitates the dissolution and absorption of oxygen within the bloodstream and tissues.
As patients breathe in this enriched oxygen environment, the oxygen is able to penetrate deeper into the body, reaching areas that may be suffering from inadequate blood flow or oxygen supply due to injury, disease, or other factors. MHBOT thus offers a targeted and effective means of supplying oxygen to these potentially deprived tissues.
China stands as a pioneer in the adoption of MHBOT, with a comprehensive network of 2,107 hospitals nationwide (encompassing mainland China, Hong Kong, Macau, and Taiwan) equipped with medical-grade hyperbaric oxygen chambers. The impressive total of over 5,600 such chambers underscores the widespread acceptance and implementation of this therapy, reflecting China's commitment to providing advanced medical treatments to its citizens.
2019 Nobel Prize in Physiology or Medicine Results Explained
Oxygen utilisation and regulation are essential for the survival of higher life, and three scientists, William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza, have been awarded the 2019 Nobel Prize in Physiology or Medicine for their discovery of a mechanism related to cellular sensing and adaptation to oxygen availability. They discovered that hypoxia-inducible factor 1 (HIF-1) is widely present in acute and chronic hypoxic cells and is an important transcription factor for cellular adaptation to hypoxia.HIF-1 levels are regulated by oxygen content. Under hyperoxia, HIF-1 is modified and then degraded; under hypoxia, HIF-1 is not degraded and causes the expression of hypoxia-related genes, such as erythropoietin, through transcriptional regulation. This article introduces the discovery and basic molecular mechanism of HIF-1, and discusses its value in clinical application.
The major discovery of William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza in the pathway of hypoxia-inducible factor has laid the foundation for the study of the mechanism of cellular adaptation to hypoxia and opened a whole new horizon for researchers, which will pave the way for research and treatment of a variety of diseases such as anaemia, tumours and ischemic-hypoxic diseases. mechanism of anaemia, tumour and ischemic-hypoxic diseases, paving the way for research and treatment. Subsequent studies have broadened the regulatory network of the HIF pathway, and through a large number of scientific experiments and clinical studies, a variety of therapeutic drugs have been developed, bringing a new turn to the prevention and treatment of diseases. With scientists' further understanding of the mechanism of hypoxia adaptation, the research results in this field will also be applied to the treatment of more diseases.
Product Tags:
|
|
Improved Cognitive Sitting Hyperbaric Chamber For Single Person WEIZI Images
|
